BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jan 20, 2003
 |  BioCentury  |  Product Development

Actelion discounts Viagra threat

Actelion Ltd. isn't yet losing sleep over potential competition from phosphodiesterase-5 inhibitors for pulmonary arterial hypertension (PAH), the market for ATLN's Tracleer bosentan oral endothelin receptor A and B antagonist. Despite analyst worries about competition from Pfizer Inc.'s Viagra sildenafil, ATLN says it's not news that PDE-5 inhibitors are being investigated in PAH, and that the real question is whether chronic administration of the drugs at high doses will prove to be safe (see B14).

"PDE-5 inhibitors are on the horizon, and we have spoken about it for months," said Roland Haefeli, a spokesperson for Actelion (SWX:ATLN, Allschwil, Switzerland). "But whether there is a future for this specific drug in PAH remains highly questionable at this time, with neither robust...

Read the full 609 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >